Previous studies with cholinesterase inhibitors in patients with Alzheimer's Disease (AD), and the ongoing multi-center study of THA, suggests that a subgroup of patients with (AD) are responsive to this pharmacological intervention. However, a substantial proportion of patients are virtually unaffected by the administration of cholinesterase inhibitors. Data generated in animals with combined lesions of the nucleus basalis and locus coeruleus indicate that the addition of a locus coeruleus lesion to animals with nucleus basalis lesion completely eliminated responsivity to cholinomimetic agents. However the administration of the alpha II agonist clonidine, combined with a cholinomimetic, restores the ability of the cholinomimetic compound to reverse the poor performance associated with a nucleus basalis lesion. These data suggest that it is essential to the efficacy of a cholinergic compound that there be an intact central noradrenergic system. In addition these data constitute the foundation of a hypothesis proposing that some of the nonresponsivity to cholinomimetic agents, and the variable therapeutic effects observed following the administration of these compounds, may be a manifestation of variable noradrenergic degeneration in the AD brain. Specifically, those Alzheimer;s patients with a profound noradrenergic deficit would be anticipated to have no alleviation of symptoms following the administration of a cholinesterase inhibitor. In order to test this hypothesis a series of antemortem noradrenergic markers will be investigated for the possibility that they will be predictive of responsivity to the cholinesterase inhibitor THA alone combined with either clonidine, deprenyl, or desipramine. In a second parallel investigation the validity of these antemortem noradrenergic markers will be tested in a separate cohort of new stage Alzheimer;s patients whose antemortem parameters will be composed with the changes on post mortem examination in noradrenergic parameters when these same Alzheimer;s patients are autopsied.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005138-07
Application #
3809200
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Mitchell, A C; Javidfar, B; Pothula, V et al. (2018) MEF2C transcription factor is associated with the genetic and epigenetic risk architecture of schizophrenia and improves cognition in mice. Mol Psychiatry 23:123-132
Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17
Munger, Emily L; Edler, Melissa K; Hopkins, William D et al. (2018) Astrocytic changes with aging and Alzheimer's disease-type pathology in chimpanzees. J Comp Neurol :
Wilmoth, Kristin; LoBue, Christian; Clem, Matthew A et al. (2018) Consistency of traumatic brain injury reporting in older adults with and without cognitive impairment. Clin Neuropsychol 32:524-529
Hadjichrysanthou, Christoforos; McRae-McKee, Kevin; Evans, Stephanie et al. (2018) Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies. J Alzheimers Dis 66:587-600
Mincer, Joshua S; Baxter, Mark G; McCormick, Patrick J et al. (2018) Delineating the Trajectory of Cognitive Recovery From General Anesthesia in Older Adults: Design and Rationale of the TORIE (Trajectory of Recovery in the Elderly) Project. Anesth Analg 126:1675-1683
Hanfelt, John J; Peng, Limin; Goldstein, Felicia C et al. (2018) Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. Neurobiol Dis 117:62-71
Ting, Simon Kang Seng; Foo, Heidi; Chia, Pei Shi et al. (2018) Dyslexic Characteristics of Chinese-Speaking Semantic Variant of Primary Progressive Aphasia. J Neuropsychiatry Clin Neurosci 30:31-37
Bryois, Julien; Garrett, Melanie E; Song, Lingyun et al. (2018) Evaluation of chromatin accessibility in prefrontal cortex of individuals with schizophrenia. Nat Commun 9:3121
Miller, M L; Ren, Y; Szutorisz, H et al. (2018) Ventral striatal regulation of CREM mediates impulsive action and drug addiction vulnerability. Mol Psychiatry 23:1328-1335

Showing the most recent 10 out of 555 publications